---
title: "SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Product information and disease description"
description: "Formulary evidence on SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Product information and disease description. Covers Product description and Place of product in therapy. 94 evidence topics quoted from 53 sources."
canonical: "https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### FDA approval status

> “Not FDA Approved for Orphan Indication”

Source: [FDA Orphan Drug Designations and Approvals (1990)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=45290)

<a id="topic-2.1.1-2"></a>

##### FDA submission and anticipated action date

> “Saol resubmitted the NDA on June 30, 2026,”
> “a Prescription Drug User Fee Act (PDUFA) target action date of Dec. 30, 2026.”

Source: [Saol Therapeutics NDA resubmission acceptance announcement (2026)](https://www.prnewswire.com/news-releases/saol-therapeutics-announces-the-acceptance-of-resubmission-of-sl1009-dca-by-the-fda-with-pdufa-date-of-dec-30-2026-302836586.html)

<a id="topic-2.1.1-3"></a>

##### Regulatory status: Under review; NDA resubmitted June 2026 and accepted July 2026

> “Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026”
> “ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, July 28, 2026”
> “The FDA acknowledged the resubmission as complete, classified it as Class 2, and set a Prescription Drug User Fee Act (PDUFA) target action date of Dec. 30, 2026.”
> “Saol resubmitted the NDA on June 30, 2026, after a productive Type A meeting in December 2025 and a Type C meeting in March 2026.”

Source: [Saol Therapeutics NDA resubmission acceptance announcement (2026)](https://www.prnewswire.com/news-releases/saol-therapeutics-announces-the-acceptance-of-resubmission-of-sl1009-dca-by-the-fda-with-pdufa-date-of-dec-30-2026-302836586.html)

<a id="topic-2.1.1-4"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-5"></a>

##### Resubmission classification

> “The FDA acknowledged the resubmission as complete, classified it as Class 2,”

Source: [Saol Therapeutics NDA resubmission acceptance announcement (2026)](https://www.prnewswire.com/news-releases/saol-therapeutics-announces-the-acceptance-of-resubmission-of-sl1009-dca-by-the-fda-with-pdufa-date-of-dec-30-2026-302836586.html)

<a id="topic-2.1.1-6"></a>

##### Special FDA designations

> “06/11/1990”
> “Treatment of congenital lactic acidosis”

Source: [FDA Orphan Drug Designations and Approvals (1990)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=45290)

<a id="topic-2.1.1-7"></a>

##### Fast Track designation

> “the FDA has granted Fast Track Designation for Dichloroacetate (DCA, SL-1009)”

Source: [Saol Therapeutics Fast Track designation announcement (2024)](https://saolrx.com/saol-therapeutics-receives-fast-track-designation-for-treatment-of-rare-mitochondrial-disease-pyruvate-dehydrogenase-complex-deficiency-pdcd/)

<a id="topic-2.1.1-8"></a>

##### Additional FDA designations

> “SL1009 has been granted Orphan Drug, Priority Review, and Rare Pediatric Disease Designations by the FDA.”

Source: [Saol Therapeutics Type A meeting announcement (2025)](https://saolrx.com/saol-therapeutics-has-been-granted-a-type-a-meeting-with-the-fda-to-determine-the-path-forward-for-sl1009-in-pyruvate-dehydrogenase-complex-deficiency-pdcd/)

<a id="topic-2.1.1-9"></a>

##### FDA Advisory Committee

> “No concerns were raised by the FDA about the adequacy of the filing or the need for an advisory committee meeting.”

Source: [Saol Therapeutics clinical milestones announcement (2025)](https://saolrx.com/saol-therapeutics-announces-major-clinical-milestones-across-multiple-development-programs/)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Saol Therapeutics

> “Sponsor: Saol Therapeutics Inc.”

Source: [FDA Orphan Drug Designations and Approvals (1990)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=45290)

<a id="topic-2.1.2.1-2"></a>

###### Development code and product name

> “SL1009, Sodium Dichloroacetate Oral Solution (DCA)”

Source: [Saol Therapeutics Type A meeting announcement (2025)](https://saolrx.com/saol-therapeutics-has-been-granted-a-type-a-meeting-with-the-fda-to-determine-the-path-forward-for-sl1009-in-pyruvate-dehydrogenase-complex-deficiency-pdcd/)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Dosage form

> “Oral Solution”

Source: [Saol Therapeutics](https://saolrx.com/pipeline)

<a id="topic-2.1.2.2-2"></a>

###### Solution strength

No evidence found.

<a id="topic-2.1.2.2-3"></a>

###### Material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Pharmacologic classification

> “inhibits Pyruvate Dehydrogenase Kinase (PDK)”

Source: [Saol Therapeutics NDA acceptance announcement (2025)](https://saolrx.com/saol-therapeutics-announces-fda-acceptance-of-new-drug-application-for-sl1009-for-treatment-of-pyruvate-dehydrogenase-complex-deficiency/)

<a id="topic-2.1.2.4-2"></a>

###### AHFS classification code

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Proposed indication

> “for the treatment of pyruvate dehydrogenase complex deficiency (PDCD)”

Source: [Saol Therapeutics NDA resubmission announcement (2026)](https://saolrx.com/saol-therapeutics-resubmits-the-new-drug-application-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-an-ultra-rare-disease/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Proposed mechanism of action

> “inhibits Pyruvate Dehydrogenase Kinase (PDK) to stimulate residual Pyruvate Dehydrogenase Complex (PDC) activity and increase energy (ATP) production by mitochondria.”

Source: [Saol Therapeutics NDA acceptance announcement (2025)](https://saolrx.com/saol-therapeutics-announces-fda-acceptance-of-new-drug-application-for-sl1009-for-treatment-of-pyruvate-dehydrogenase-complex-deficiency/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical peripheral nerve effects

> “Both juvenile and adult rats treated with DCA developed nerve conduction slowing that was more pronounced in adult rats.”

Source: [Calcutt et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2741559/)

<a id="topic-2.1.2.6.2-2"></a>

###### Preclinical nematode model: preprint

> “Significantly improved health, survival, tissue lactate levels, and mitochondrial physiology were observed at 25 mM in pdha-1(RNAi) knockdown animals.”

Source: [Remes et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13370984/)

<a id="topic-2.1.2.6.2-3"></a>

###### Historical clinical review of dichloroacetate response

> “The case histories of 46 subjects were analyzed with regard to diagnosis, clinical presentation and response to DCA.”

Source: [Berendzen et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16725381/)

Additional sources: [Morten et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10449128/); [Han et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18206410/); [Stacpoole et al. (1997)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1717417/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Absorption and distribution

> “An oral dose of DCA is rapidly absorbed and widely distributed within minutes of administration.”

Source: [James et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5274567/)

<a id="topic-2.1.2.6.3-2"></a>

###### Central nervous system distribution

> “It readily crosses the blood-brain barrier and can be measured in cerebrospinal fluid.”

Source: [James et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5274567/)

<a id="topic-2.1.2.6.3-3"></a>

###### Metabolism and inhibition of clearance

> “DCA inhibits GSTZ1/MAAI, leading to delayed plasma drug clearance and to accumulation of potentially toxic tyrosine intermediates.”

Source: [Shroads et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4276489/)

<a id="topic-2.1.2.6.3-4"></a>

###### Repeated dosing and phenoconversion

> “DCA-induced inactivation of GSTZ1 resulted in phenoconversion of all subjects into slow metabolizers after repeated dosing.”

Source: [Mangal et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5967850/)

<a id="topic-2.1.2.6.3-5"></a>

###### Chronic dosing and accumulation

> “Chronic administration of DCA leads to inhibition of DCA metabolism and potential accumulation to levels that result in side effects.”

Source: [James and Stacpoole (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5558523/)

<a id="topic-2.1.2.6.3-6"></a>

###### Metabolic autoinhibition

> “DCA inhibits GSTz1/MAAI, which leads to a marked decrease in its plasma clearance.”

Source: [Shroads et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3786668/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Investigational treatment: clinically limiting toxicity

> “The main clinically limiting toxicity is reversible peripheral neuropathy.”

Source: [James et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5274567/)

<a id="topic-2.1.2.7.1-2"></a>

###### Chronic exposure: sensory and motor neuropathy

> “A reversible sensory/motor peripheral neuropathy is the clinically limiting adverse effect of chronic DCA exposure”

Source: [Stacpoole et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31208525/)

<a id="topic-2.1.2.7.1-3"></a>

###### Neuropathy character, dose dependence, and time to resolution

> “DCA therefore appears to induce a dose-dependent, largely reversible, distal peripheral neuropathy that afflicts large and small fibers of motor and sensory nerves and causes both sensory loss and pain.”
> “In all studies, peripheral neuropathy generally resolved over 6–18 months following dose de-escalation or discontinuation, although in some cases it persisted.”

Source: [Stacpoole et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31208525/)

<a id="topic-2.1.2.7.1-4"></a>

###### Neuropathy risk by age

> “Clinical descriptions of DCA-induced peripheral neuropathy have emphasized that it is more common and severe in adults than children”
> “In liver, cytosolic GSTZ1 expression (the dominant cellular fraction) reaches adult levels at around 7 years of age, while the mitochondrial form only reaches maximal expression and activity at around 21 years of age”
> “This explanation is supported by the finding that DCA clearance is reduced less in children than adults following 6 months DCA treatment”

Source: [Stacpoole et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31208525/)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Age-related pharmacokinetics

> “a striking age-dependent decrease in its plasma clearance and an increase in its plasma half-life in patients and rats.”

Source: [Shroads et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2613565/)

<a id="topic-2.1.2.8-2"></a>

###### Pregnancy, lactation, and reproductive potential

No evidence found.

<a id="topic-2.1.2.8-3"></a>

###### Renal impairment: SL1009-specific dosing

No evidence found.

<a id="topic-2.1.2.8-4"></a>

###### Hepatic impairment: SL1009-specific dosing

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Sodium dichloroacetate

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Sodium dichloroacetate on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Genotype-directed dosing in the phase 3 trial

> ““fast” (12.5mg/kg/12h) or “slow” (6.25mg/kg/12h) DCA metabolizer”

Source: [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/)

<a id="topic-2.1.2.10.1-2"></a>

###### Dose-determining genetic test

> “The test identifies each patient's GSTZ1 genotype to provide individualized dosing intended to reduce adverse events, such as peripheral neuropathy.”

Source: [Saol Therapeutics NDA submission announcement (2024)](https://saolrx.com/saol-therapeutics-announces-submission-of-new-drug-application-nda-to-the-u-s-fda-for-sl1009/)

<a id="topic-2.1.2.10.1-3"></a>

###### Clinical pharmacogenetic test validation

> “The clinical genetic test for GSTZ1 was developed and validated at our CLIA-certified Clinical Laboratory.”

Source: [Langaee et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29641284/)

<a id="topic-2.1.2.10.1-4"></a>

###### Companion diagnostic: planned submission pathway

> “will be filing a 510K for the dose-determining genetic test”

Source: [Saol Therapeutics NDA resubmission acceptance announcement (2026)](https://www.prnewswire.com/news-releases/saol-therapeutics-announces-the-acceptance-of-resubmission-of-sl1009-dca-by-the-fda-with-pdufa-date-of-dec-30-2026-302836586.html)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Clinical administration routes

> “by mouth or feeding tube”

Source: [James et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5274567/)

<a id="topic-2.1.2.10.2-2"></a>

###### SL1009 administration relative to food

No evidence found.

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Expanded access: NCT06931262

> “The patient is not eligible to participate in a clinical trial.”
> “The patient’s licensed physician (“physician”) submits an unsolicited request for expanded access.”

Source: [Saol Therapeutics expanded access program policy](https://saolrx.com/expanded-access-program-policy/)

<a id="topic-2.1.2.11-2"></a>

###### Expanded-access request responsibility

> “Only a qualified, licensed, treating physician may submit a request for expanded access to DCA for PDCD.”

Source: [Saol Therapeutics expanded access program policy](https://saolrx.com/expanded-access-program-policy/)

<a id="topic-2.1.2.11-3"></a>

###### Genetic counseling and clinical-trial access

> “After speaking with a genetic counselor, families interested in learning more about the clinical research study will be connected with a trial site.”

Source: [Saol Therapeutics and InformedDNA (2022)](https://saolrx.com/saol-therapeutics-and-informeddna-partner-to-offer-genetic-counseling-to-patients-with-rare-mitochondrial-disease/)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Phase 3 background treatment

> “Enrolled subjects continued their ketogenic diets and other supplements.”

Source: [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Sodium dichloroacetate on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Review of investigational dichloroacetate and phenylbutyrate

> “This review analysed the efficacy of dichloroacetate and phenylbutyrate as potential treatments for PDH deficiency caused by PDHA1 pathogenic variants.”

Source: [Karissa et al. (2022)](https://www.frontierspartnerships.org/journals/british-journal-of-biomedical-science/articles/10.3389/bjbs.2022.10382/full)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Genetic basis of disease

> “PDCD is caused by abnormalities in the genes that encode the components of the pyruvate dehydrogenase complex.”

Source: [Saol Therapeutics](https://saolrx.com/pipeline)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Pyruvate dehydrogenase complex deficiency

<a id="topic-2.2.1.2.1-1"></a>

###### U.S. incidence estimate

> “1 in 40,000 live births, approximately 90 newborns annually”

Source: [Saol Therapeutics complete response letter announcement (2025)](https://www.prnewswire.com/news-releases/saol-therapeutics-receives-complete-response-letter-from-fda-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-302548522.html)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Pyruvate dehydrogenase complex deficiency

<a id="topic-2.2.1.2.2-1"></a>

###### U.S. prevalence estimate

> “fewer than 1,000 individuals in the U.S.”

Source: [Saol Therapeutics complete response letter announcement (2025)](https://www.prnewswire.com/news-releases/saol-therapeutics-receives-complete-response-letter-from-fda-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-302548522.html)

<a id="topic-2.2.1.2.2-2"></a>

###### Swedish population-based cohort and birth prevalence

> “54 patients (35 female patients)”
> “birth prevalence of 2.43 per 100,000 live births (95% CI 1.86–3.17)”

Source: [Savvidou et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13089191/)

<a id="topic-2.2.1.2.2-3"></a>

###### Swedish point prevalence

> “a point prevalence of 0.44 per 100,000 population (95% CI 0.40-0.65).”

Source: [Savvidou et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13089191/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Natural history and mortality

> “39% of these subjects (23/59) have died.”
> “Causes of death included severe lactic acidosis, respiratory failure, and infection.”

Source: [DeBrosse et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23021068/)

<a id="topic-2.2.1.3-2"></a>

###### Age at death and mortality by sex

> “Of these, 91% (21/23) died before age 4 years, 61% (14/23) before 1 year, and 43% (10/23) before 3 months.”
> “56% of males died compared with 25% of females.”
> “Neonatal or infant onset of symptoms was associated with poor outcomes. Males with PDHA1 mutations and low fibroblast PDC activity were less likely to survive beyond infancy.”

Source: [DeBrosse et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23021068/)

<a id="topic-2.2.1.3-3"></a>

###### Swedish population-based cohort: mortality

> “Eight patients (15%) died during the study period.”

Source: [Savvidou et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13089191/)

<a id="topic-2.2.1.3-4"></a>

###### Additional genotype, phenotype, and natural-history evidence

> “Data from 891 individuals (45% unpublished) were included.”

Source: [Merkevicius et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13337232/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Pathophysiology and disease consequences

> “chronic energy deficit leading to lactic acidosis, profound developmental problems, and early childhood death.”

Source: [Saol Therapeutics NDA resubmission announcement (2026)](https://saolrx.com/saol-therapeutics-resubmits-the-new-drug-application-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-an-ultra-rare-disease/)

<a id="topic-2.2.1.4-2"></a>

###### Impaired pyruvate metabolism

> “pyruvate cannot be metabolized into acetyl‐CoA, resulting in a mitochondrial disorder with lactic acidosis, seizures, and severe encephalopathy.”

Source: [Kossoff et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5983110/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Molecular genetic testing

> “molecular genetic testing for a mutation that causes PDCD”

Source: [United Mitochondrial Disease Foundation](https://umdf.org/pdcd/)

<a id="topic-2.2.1.5-2"></a>

###### Previously unrecognized disease in female carriers

> “We identified seven female PDHA1 carriers from five families.”
> “Five of them exhibited clinical features of the disease and were previously undiagnosed”

Source: [Savvidou et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/ene.16283)

<a id="topic-2.2.1.5-3"></a>

###### Investigational amino-acid screening ratios

> “Ala/Lys ≥3.0 and Ala/Leu ≥5.0”
> “identified patients with PDCD with 100% SN and ~85% SP.”

Source: [Verma et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mgg3.2283)

Additional sources: [Shin et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28918066/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Neurodevelopmental and motor symptoms

> “Neurodevelopmental delay and hypotonia were the commonest clinical signs of PDC deficiency.”

Source: [Patel et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4003492/)

<a id="topic-2.2.1.6-2"></a>

###### Structural brain abnormalities

> “ventriculomegaly, dysgenesis of the corpus callosum”

Source: [Patel et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4003492/)

<a id="topic-2.2.1.6-3"></a>

###### Epilepsy

> “Lifetime epilepsy was present in 16/41 (39%) of individuals.”

Source: [Savvidou et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13445312/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Cognitive and adaptive functioning

> “Intellectual disability was detected in 33/42 (79%) individuals, while 31/35 (89%) demonstrated significant impairments in adaptive functioning.”

Source: [Savvidou et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13445312/)

<a id="topic-2.2.1.7-2"></a>

###### Distribution of intellectual outcomes among survivors

> “Of 42 subjects whose intellectual abilities were professionally evaluated, 19% had normal or borderline intellectual ability (CQ/IQ ≥ 70), 10% had mild intellectual disability (ID) (CQ/IQ 55–69), 17% had moderate ID (CQ/IQ 40–54), 24% had severe ID (CQ/IQ 25–39) and 33% had profound ID (CQ/IQ < 25).”
> “The average outcome for females was severe-to-profound ID, whereas that of males was mild-to-moderate ID.”
> “Of 10 subjects who reached age 12 years, 9 had had professional IQ assessments, and only 4 had IQs ≥ 70”

Source: [DeBrosse et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23021068/)

<a id="topic-2.2.1.7-3"></a>

###### Ambulation and age-appropriate walking

> “Although 27/39 (69%) were ambulatory, only 8/39 (21%) demonstrated age‐appropriate walking ability.”

Source: [Savvidou et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13445312/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Pyruvate dehydrogenase complex deficiency

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Patient-reported disease burden

> “More than 84% of survey respondents cited muscle weakness as one of the three most impactful symptoms”

Source: [UMDF and MitoAction (2023)](https://umdf.org/wp-content/uploads/2023/12/PDCD_Report_Final.pdf)

<a id="topic-2.2.1.8.1-2"></a>

###### Caregiver burden: broader mitochondrial disease

> “often resulting in poor functional and survival outcomes for the patient and considerable psychosocial distress for the caregiver.”

Source: [Sofou (2013)](https://pubmed.ncbi.nlm.nih.gov/23529909/)

<a id="topic-2.2.1.8.1-3"></a>

###### Broader mitochondrial disease review: utility evidence

> “No studies reported utilities data.”

Source: [Bertini et al. (2023)](https://link.springer.com/article/10.1186/s13023-023-02945-6)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Broader mitochondrial-disease population: Ontario, Canada

> “(mean = CAD$24,023 in 12 months before first hospitalization)”
> “within the single-payer Ontario health care system.”

Source: [Buajitti et al. (2022)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0265744)

<a id="topic-2.2.1.8.2-2"></a>

###### Broader mitochondrial disease: U.S. healthcare costs

> “Total allowed per member per month (PMPM) cost for pediatric patients was $4829 and $3100 for adults”

Source: [Cohen et al. (2018)](https://link.springer.com/article/10.1186/s13023-018-0949-5)

<a id="topic-2.2.1.8.2-3"></a>

###### Broader mitochondrial disease: treatment costs in China

> “The average monthly treatment cost was 3000 RMB for children and 3100 RMB for adults.”

Source: [Zhao et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03289-5)

<a id="topic-2.2.1.8.2-4"></a>

###### Broader mitochondrial disease review: cost evidence

> “No studies reported costs data.”

Source: [Bertini et al. (2023)](https://link.springer.com/article/10.1186/s13023-023-02945-6)

<a id="topic-2.2.1.8.2-5"></a>

###### Patient employment: adult PDCD

> “This limits his ability to work”

Source: [UMDF and MitoAction (2023)](https://umdf.org/wp-content/uploads/2023/12/PDCD_Report_Final.pdf)

Additional sources: [Schofield et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40490132/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Pyruvate dehydrogenase complex deficiency on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Broader mitochondrial disease: Australian household costs

> “We estimated total annual average costs at AU$ 112 721 per household.”
> “a large proportion were societal costs (92%).”

Source: [Schofield et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40490132/)

<a id="topic-2.2.1.8.3-2"></a>

###### PDCD-specific household and caregiver costs

No evidence found.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Broader mitochondrial and rare disorders: proteomics micro-costing

> “reported in 2023 Australian dollars (AUD).”
> “At an estimated average cost of $897 (US $607) per test”

Source: [Santos Gonzalez et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03462-w)

<a id="topic-2.2.1.8.4-2"></a>

###### SL1009 dose-determining genetic test cost

No evidence found.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Ketogenic Dietary Therapy

<a id="topic-2.2.2.1.1-1"></a>

###### Primary PDCD management

> “Ketogenic diet is the gold-standard therapy for individuals with primary PDCD”
> “Tolerance of the ketogenic diet varies and treatment must be individualized.”

Source: [Ganetzky et al. (2021)](https://www.ncbi.nlm.nih.gov/books/NBK571223/)

<a id="topic-2.2.2.1.1-2"></a>

###### Ketogenic-diet clinical evidence

> “Nineteen patients were assessed”

Source: [Sofou et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5306430/)

<a id="topic-2.2.2.1.1-3"></a>

###### Ketogenic diet therapies: International Ketogenic Diet Study Group recommendations

> “KDTs are the treatment of first choice for 2 distinct disorders of brain energy metabolism: Glut1DS and PDHD.”

Source: [Kossoff et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5983110/)

<a id="topic-2.2.2.1.1-4"></a>

###### Ketogenic-diet literature review and clinical-practice survey

> “Forty studies describing 129 patients were identified, predominantly case reports or series.”

Source: [Madsen et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42341672/)

<a id="topic-2.2.2.1.1-5"></a>

###### Reported use of ketogenic diet in a natural-history cohort

> “The next most common intervention was dietary, with 60% (35/58) of the subjects reportedly having used a “ketogenic” diet at some time.”
> “Altogether, 83% (24/29) of responding families reported that use of a ketogenic diet was “very helpful”, 10% said it was “somewhat helpful”, and 7% reported that it was “not helpful””
> “No significant correlation was found between use of ketogenic diets and survival or cognitive function outcomes, which is not surprising since use of ketogenic diets varied by degree of severity, duration, and age of administration.”
> “ketogenic diet therapy does not reverse prior neurological damage and is not effective in sustaining survival in the most severe cases of PDC deficiency.”

Source: [DeBrosse et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23021068/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Vitamin and Cofactor Supplementation

<a id="topic-2.2.2.1.2-1"></a>

###### Thiamine supplementation

> “thiamine (may benefit rare individuals)”

Source: [United Mitochondrial Disease Foundation](https://umdf.org/pdcd/)

<a id="topic-2.2.2.1.2-2"></a>

###### Reported use of thiamine in a natural-history cohort

> “Thiamine was the most frequently employed intervention, with 68% (39/57) of subjects reporting some use.”
> “Doses ranged widely from 25 mg to 2000 mg/day (average dose: 174 mg; median dose: 150 mg/dl).”
> “No subject reportedly had a remarkable beneficial response to thiamine treatment.”

Source: [DeBrosse et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23021068/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Rehabilitation and Supportive Care

<a id="topic-2.2.2.1.3-1"></a>

###### Muscle function and rehabilitation

> “physical and occupational therapy to help with muscle function”

Source: [United Mitochondrial Disease Foundation](https://umdf.org/pdcd/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Symptom-directed Neurologic Therapies

<a id="topic-2.2.2.1.4-1"></a>

###### Seizure management

> “Standard anti-seizure therapy as needed”

Source: [Ganetzky et al. (2021)](https://www.ncbi.nlm.nih.gov/books/NBK571223/)

<a id="topic-2.2.2.1.4-2"></a>

###### Paroxysmal dystonia

> “Benzodiazepines”

Source: [Ganetzky et al. (2021)](https://www.ncbi.nlm.nih.gov/books/NBK571223/)

<a id="topic-2.2.2.1.4-3"></a>

###### Chronic dystonia

> “Botulinum toxin injections”

Source: [Ganetzky et al. (2021)](https://www.ncbi.nlm.nih.gov/books/NBK571223/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Buffer Therapy for Acidosis

<a id="topic-2.2.2.1.5-1"></a>

###### Correction of acidosis

> “Bicarbonate or buffer therapy”

Source: [Ganetzky et al. (2021)](https://www.ncbi.nlm.nih.gov/books/NBK571223/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Genotype-specific Metabolic Management

<a id="topic-2.2.2.1.6-1"></a>

###### DLD-related disease: dietary and acute metabolic management

> “Branched-chain amino acid restriction”
> “Dextrose-containing IV fluids”

Source: [Ganetzky et al. (2021)](https://www.ncbi.nlm.nih.gov/books/NBK571223/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary

Ketogenic dietary treatment must be individualized because tolerance varies. A clinical-practice review identified 40 studies describing 129 participants, predominantly case reports or case series. A separate treatment scoping review included seven preclinical and ten human studies and concluded that most interventions had not been rigorously investigated. These evidence designs limit the certainty of comparative treatment effects.

Source: [Ganetzky et al. (2021)](https://www.ncbi.nlm.nih.gov/books/NBK571223/); [Madsen et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42341672/); [Betesh-Abay et al. (2026)](https://cris.bgu.ac.il/en/publications/pyruvate-dehydrogenase-complex-deficiency-a-review-of-treatments-/)

<a id="topic-2.2.2.1.7-2"></a>

###### Unmet treatment need

> “There are currently no FDA-approved therapies for PDCD.”

Source: [Saol Therapeutics NDA resubmission announcement (2026)](https://saolrx.com/saol-therapeutics-resubmits-the-new-drug-application-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-an-ultra-rare-disease/)

<a id="topic-2.2.2.1.7-3"></a>

###### Cochrane review: mitochondrial disorders, literature search through July 2011

> “three trials in children showed a statistically significant improvement in biochemical measurements but no clinical benefit on physiological measurements and exercise tests”

Source: [Pfeffer et al. (2021)](https://www.cochrane.org/evidence/CD004426_treatment-mitochondrial-disorders)

<a id="topic-2.2.2.1.7-4"></a>

###### PDCD scoping review and case series

> “We reviewed and summarized findings from seven preclinical studies and ten human studies”
> “However, most interventions have yet to be rigorously investigated.”

Source: [Betesh-Abay et al. (2026)](https://cris.bgu.ac.il/en/publications/pyruvate-dehydrogenase-complex-deficiency-a-review-of-treatments-/)

<a id="topic-2.2.2.1.7-5"></a>

###### Natural-history cohort: absence of demonstrated benefit for any intervention

> “Five subjects had used DCA, and one family reported that it was “very helpful”.”
> “Subjective retrospective assessments of the benefits of these various interventions were most favorable for ketogenic diet treatment, but we cannot confidently determine from these data benefit or lack thereof for any of these interventions.”
> “This retrospective correlation of PDC activity, mutations, and outcomes was not designed to assess whether specific treatments were effective in improving outcomes.”

Source: [DeBrosse et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23021068/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

SL1009 is an investigational oral treatment with genotype-directed dosing. In the phase 3 study, participants continued ketogenic diets and other supplements; the available evidence therefore concerns use with background treatment rather than replacement of that care. The application remains under FDA review, with a target action date of December 30, 2026. Expanded access is physician-directed, and the published policy requires that the patient be ineligible for a clinical trial and that a licensed treating physician submit the request.

Source: [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/); [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/); [Saol Therapeutics NDA resubmission acceptance announcement (2026)](https://www.prnewswire.com/news-releases/saol-therapeutics-announces-the-acceptance-of-resubmission-of-sl1009-dca-by-the-fda-with-pdufa-date-of-dec-30-2026-302836586.html); [Saol Therapeutics expanded access program policy](https://saolrx.com/expanded-access-program-policy/); [Saol Therapeutics](https://saolrx.com/pipeline)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Ketogenic diet: disease phenotype and ketosis

> “Treatment effect was mainly determined by disease phenotype and attainment and maintenance of ketosis.”

Source: [Sofou et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5306430/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Paroxysmal dystonia: minimizing provoking stressors

> “Minimize stressors (e.g., fever).”

Source: [Ganetzky et al. (2021)](https://www.ncbi.nlm.nih.gov/books/NBK571223/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

<a id="topic-2.2.2.5-1"></a>

###### Original FDA requirement for additional effectiveness evidence

> “at least one new adequate and well-controlled trial”

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="topic-2.2.2.5-2"></a>

###### FDA-requested cardiac electrophysiology evaluation

> “Conduct a thorough QT/QTc study”

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="topic-2.2.2.5-3"></a>

###### FDA-requested food-effect evaluation

> “effect of food on the PK of DCA.”

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="topic-2.2.2.5-4"></a>

###### Subsequent sponsor-reported resubmission pathway

> “proceed directly to resubmission without conducting an additional trial”

Source: [Saol Therapeutics NDA resubmission announcement (2026)](https://saolrx.com/saol-therapeutics-resubmits-the-new-drug-application-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-an-ultra-rare-disease/)

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Investigational biochemical outcome

> “A key secondary endpoint measured the reduction in plasma lactate of SL1009 compared to placebo.”

Source: [Saol Therapeutics NDA submission announcement (2024)](https://saolrx.com/saol-therapeutics-announces-submission-of-new-drug-application-nda-to-the-u-s-fda-for-sl1009/)

## Related pages
- [SL1009 (sodium dichloroacetate): Pyruvate dehydrogenase complex deficiency](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Terms and abbreviations](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/terms-and-abbreviations.md)
- [SL1009 (sodium dichloroacetate): Pyruvate dehydrogenase complex deficiency](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/executive-summary) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/executive-summary.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Clinical evidence](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/clinical-evidence.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Economic information and modeling report](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/economics) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/economics.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: References](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/references) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/references.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: prevalence by geography](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/prevalence) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/prevalence.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/cost-effectiveness-analyses.md)
